4.2 Article

Cardiovascular complications after transplantation: Treatment options in solid organ recipients

Journal

TRANSPLANTATION REVIEWS
Volume 28, Issue 2, Pages 47-55

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.trre.2013.12.001

Keywords

-

Funding

  1. Sanofi Aventis
  2. Novartis
  3. Merke Sharpe Dome
  4. Astellas

Ask authors/readers for more resources

Premature cardiovascular disease is the commonest cause of death in solid organ transplant recipients, with coronary artery disease, sudden cardiac death and heart failure being highly prevalent. There are unique factors leading to CV disease in organ transplant recipients that include underlying comorbidities, and metabolic effects of immunosuppression. As a consequence management strategies developed in the general population may have limited benefit. In this review, we will focus on renal transplantation, where most research has been carried out and, despite incomplete understanding of the disease process, the incidence of cardiovascular disease appears to be falling. (C) 2014 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available